Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

GAUZ Investors Have Opportunity to Lead Gauzy Ltd. ...

Summary by endpoints.news
With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt to take on AstraZeneca's EGFR inhibitor Tagrisso. CEO Jean Cui ...

3 Articles

WRICWRIC
Reposted by
icrowdresearch.comicrowdresearch.com
Center

GAUZ Investors Have Opportunity to Lead Gauzy Ltd. ...

·Richmond, United States
Read Full Article
endpoints.newsendpoints.news

BlossomHill gets another $84M for macrocyclic approach to EGFR

With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt to take on AstraZeneca's EGFR inhibitor Tagrisso. CEO Jean Cui ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Wednesday, December 10, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Startups icon

Startups

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal